Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data-Linkage Study
Real-world data show how new cancer treatments shift transfusion needs, helping hospitals plan blood supplies more effectively.
This population-level study of 7,043 MDS/CMML patients in Victoria, Australia (2009-2022) found that the introduction of 5-azacitidine in 2011 was associated with stable RBC transfusion burden but a significant increase in platelet transfusions, raising implications for blood supply planning and PLT resource optimization. The data provide a critical real-world benchmark for healthcare systems managing the growing MDS/CMML patient population.
What the study was
- Study design
- Retrospective longitudinal population cohort (data linkage)
- Population
- All MDS/CMML patients in Victoria state, Australia (population 6.5 million), 2009-2022
- Sample size
- 7043
- Category
- Public Health
- Maturity
- Validated
- Journal
- Eur J Haematol
Why it surfaced
Large population-level (n=7,043) real-world longitudinal study quantifying transfusion burden in MDS/CMML across disease-modifying therapy eras; provides actionable resource planning data for hematology services.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.